Fresenius Medical Care stock heads into a key earnings week

Published on 11/01/2026 at 17:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius Medical Care stock enters a decisive earnings week. Third-quarter results are due as investors assess growth and profitability.

Key earnings week ahead

Fresenius Medical Care will publish third-quarter results and hold its conference call on November 3.
Second-quarter net income declined year over year even as revenue increased.
Investor meetings in London and Frankfurt follow the earnings release.

FMC, DE0005785802, Illustration mit AI erstellt.

Fresenius Medical Care will publish its third-quarter 2026 results on Tuesday, November 3, and hold its conference call on the same day. The date is listed in the company's investor calendar.

Results put profitability in focus

The upcoming release follows a mixed second quarter. Fresenius Medical Care generated EUR 4.86 billion in revenue, compared with EUR 4.79 billion a year earlier, while net income fell to EUR 218 million from EUR 225.27 million. The figures cover the quarter ended June 30, 2026.

The combination leaves revenue momentum and earnings quality as the central investor questions for the third-quarter update. Management commentary on treatment volumes, operating profitability and the company's kidney-care strategy is likely to shape how investors assess the next phase of growth.

On Sunday, November 1, 2026, Fresenius Medical Care stock was quoted at 40.42 euros on Lang & Schwarz at 5:03 p.m. CET. The real-time quote of Fresenius Medical Care stock provides the latest trading reference.

More dates follow the release

The company's calendar lists a quarterly financial report for Friday, November 6. A C-level roadshow is scheduled for London on November 4 and Frankfurt on November 5, giving investors additional opportunities to assess management's outlook after the results.

Market attention will also be shaped by the broader DAX market environment.

For company-specific developments, see More news and analyses on Fresenius Medical Care stock.